New drug tested for Tough-to-Treat blood disorder
NCT ID NCT04617925
Summary
This study tested an experimental drug called belantamab mafodotin in 35 adults whose AL amyloidosis had returned or stopped responding to previous treatments. AL amyloidosis is a serious condition where abnormal proteins build up and damage organs like the heart and kidneys. The main goal was to see if the drug could effectively reduce these harmful proteins and improve how affected organs function.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AL AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre hospitalier Universitaire de Limoges -
Limoges, 87042, France
-
Fondazione I.R.C.C.S Policlinico "San Matteo"
Pavia, 27100, Italy
-
General Hospital of Athens "Alexandra"
Athens, 115 28, Greece
-
Royal Free Hospital - London,
London, United Kingdom
-
UMC Utrecht
Utrecht, 3584 CX, Netherlands
-
University Hospital Heidelberg
Heidelberg, 69120, Germany
Conditions
Explore the condition pages connected to this study.